With the glucose-dependent insulinotropic polypeptide (GIP), GLP-1 is an important incretin (Baggio & Drucker 2007) and GLP-1 agonists are widely used in the management of type 2 diabetes mellitus (Wang et al. 2022). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.